Alexandria Venture Investments portfolio companies
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| TwoStep Therapeutics | Palo Alto | Series A | $62.5M | 2026-09-09 |
| Lycia Therapeutics | South San Francisco | Series D | $75.0M | 2026-06-25 |
| Inari | Cambridge | Series G | $144.0M | 2025-01-07 |
| Triveni Bio | Watertown | Series C | $65.0M | 2026-06-17 |
| Insitro | South San Francisco | Series C | $400.0M | 2021-03-15 |
| Immunai | New York | Series B | $215.0M | 2021-10-27 |
| Capstan Therapeutics | San Diego | Series B | $175.0M | 2024-03-20 |
| Aspen Neuroscience | San Diego | Series C | $115.0M | 2025-11-20 |
8 rows of the CSV in 5 of its 18 columns.
- The 28 Alexandria Venture Investments portfolio companies have raised $5.3B in total.
- 5 of them closed their most recent round in the last 12 months, $319.1M combined.
- The largest of those rounds is Aspen Neuroscience's $115.0M Series C, dated November 2025.
- The most recent is TwoStep Therapeutics' $62.5M Series A on 9 September 2026.
- Google Ventures is an investor in 5 of them, more than any other fund.
- Biotech is the most common sector, with 27 companies (96%).
- 50% were founded in 2020 or later; the median founding year is 2020.
- The most common team size is 11 to 50 employees (54% of companies with a recorded size).
- 3 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
17 of 28| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Palo Alto, United States | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco, United States | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown, United States | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Cambridge, United States | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
| Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego, United States | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| TORL BioTherapeutics | TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing new therapies. | Biotech | Culver City, United States | Series C | $96.0M | 2025-10-07 | $412.0M | Goldman Sachs, RA Capital Management, Alexandria Venture Investments +2 | 51 to 100 | 2018 |
| AIRNA | AIRNA develops RNA editing technologies to create medicines for various diseases. | Biotech | Cambridge, United States | Series B | $155.0M | 2025-04-01 | $245.0M | ARCH Venture Partners, Alexandria Venture Investments, Forbion Capital Partners +2 | 51 to 100 | 2021 |
| Avalo | Avalo applies AI and evolutionary methods to plant biotechnology for a more sustainable food system. | Artificial intelligence | Durham, United States | Series A | $11.0M | 2025-03-06 | $14.9M | SOSV, SOSV SF & NY (Fka IndieBio), Alexandria Venture Investments +2 | 11 to 50 | 2020 |
| Inari Unicorn | Inari is a seed design and biotechnology company developing seeds for a nature-positive food system. | Biotech | Cambridge, United States | Series G | $144.0M | 2025-01-07 | $753.0M | EDBI, Alexandria Venture Investments, CPP Investments +2 | 251 to 500 | 2016 |
| Valora Therapeutics | Valora Therapeutics engineers chimeric antibodies as a biotechnology company. | Biotech | La Jolla, United States | Seed | $30.0M | 2024-11-20 | $30.0M | Correlation Ventures, Alexandria Venture Investments, TigerGene +2 | 11 to 50 | 2023 |
| Delphia Therapeutics | Delphia Therapeutics operates a laboratory that develops treatments for cancer cells. | Health care | Cambridge, United States | Series A | $67.0M | 2024-05-02 | $67.0M | Google Ventures, Polaris Partners, Alexandria Venture Investments +1 | 11 to 50 | 2022 |
| Capstan Therapeutics | Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. | Biotech | San Diego, United States | Series B | $175.0M | 2024-03-20 | $340.0M | RA Capital Management, OrbiMed, Alexandria Venture Investments +2 | 101 to 250 | 2021 |
| Elo Life Systems | Elo Life Systems is a biotechnology company that studies how food supports human health and wellness. | Biotech | Durham, United States | Series A | $20.5M | 2024-01-24 | $56.5M | Novo Holdings, Alexandria Venture Investments, DCVC Bio +2 | 11 to 50 | 2006 |
| Tome Biosciences | Tome Biosciences develops programmable gene insertion technology. | Biotech | Watertown, United States | Series A | $213.0M | 2023-12-12 | $213.0M | Andreessen Horowitz, Google Ventures, Polaris Partners +1 | 101 to 250 | 2021 |
| ROME Therapeutics | ROME Therapeutics develops therapies for cancer and autoimmune diseases by targeting the repeatome. | Biotech | Cambridge, United States | Series B | $72.0M | 2023-09-12 | $199.0M | Andreessen Horowitz, Google Ventures, Alexandria Venture Investments +2 | 11 to 50 | 2020 |
| Immunai Unicorn | Immunai applies machine learning and software engineering to map and reprogram immunology. | Artificial intelligence | New York, United States | Series B | $215.0M | 2021-10-27 | $295.0M | 8VC, TLV Partners, Alexandria Venture Investments +2 | 101 to 250 | 2018 |
| Insitro Unicorn | Insitro applies machine learning and biology to drug discovery and development. | Artificial intelligence | South San Francisco, United States | Series C | $400.0M | 2021-03-15 | $643.0M | Temasek, BlackRock, ARCH Venture Partners +1 | 251 to 500 | 2018 |
Table 1. Alexandria Venture Investments portfolio companies: the 17 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 28.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Aspen Neuroscience | Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. | Biotech | San Diego, United States | Series C | $115.0M | 2025-11-20 | $387.0M | Google Ventures, OrbiMed, EDBI +2 | 101 to 250 | 2018 |
| 2 | Lycia Therapeutics | Lycia Therapeutics develops technology using lysosome-targeting chimeras to degrade disease-causing proteins. | Biotech | South San Francisco, United States | Series D | $75.0M | 2026-06-25 | $301.6M | Franklin Templeton, Alexandria Venture Investments, Invus +1 | 11 to 50 | 2019 |
| 3 | Triveni Bio | Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. | Biotech | Watertown, United States | Series C | $65.0M | 2026-06-17 | $272.0M | Polaris Partners, OrbiMed, Alexandria Venture Investments +2 | 11 to 50 | 2019 |
| 4 | TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Palo Alto, United States | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| 5 | Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Cambridge, United States | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
Table 2. Alexandria Venture Investments portfolio companies: the 5 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Google Ventures | Corporate venture arm | San Francisco, United States | 5 | 18% | 1 | Aspen Neuroscience |
| 2 | OrbiMed | Private equity firm | New York, United States | 4 | 14% | 2 | Triveni Bio, Aspen Neuroscience |
| 3 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 4 | 14% | ||
| 4 | Polaris Partners | Private equity firm | Boston, United States | 3 | 11% | 1 | Triveni Bio |
| 5 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 3 | 11% | ||
| 6 | RA Capital Management | Startup incubator | Boston, United States | 3 | 11% | ||
| 7 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 3 | 11% | ||
| 8 | Invus | Private equity firm | New York, United States | 2 | 7% | 2 | Lycia Therapeutics, Triveni Bio |
| 9 | Blue Owl | Private equity firm | New York, United States | 2 | 7% | 1 | Lycia Therapeutics |
| 10 | EDBI | Venture capital firm | Singapore | 2 | 7% | 1 | Aspen Neuroscience |
| 11 | Catalio Capital Management | Venture capital firm | New York, United States | 2 | 7% | ||
| 12 | S32 | Venture capital firm | San Diego, United States | 2 | 7% | 1 | Aspen Neuroscience |
| 13 | Casdin Capital | Venture capital firm | New York, United States | 2 | 7% | ||
| 14 | NFX | Startup accelerator | San Francisco, United States | 1 | 4% | 1 | TwoStep Therapeutics |
| 15 | 2048 Ventures | Venture capital firm | New York, United States | 1 | 4% | 1 | TwoStep Therapeutics |
Table 3. Alexandria Venture Investments portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 27 | 96% | $5.2B |
| Health care | 23 | 82% | $4.5B |
| Software | 9 | 32% | $1.4B |
| Artificial intelligence | 7 | 25% | $1.4B |
| Hardware | 1 | 4% | $7.0M |
Table 4. Alexandria Venture Investments portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Alexandria Venture Investments portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 25 | 89% |
| Canada | 3 | 11% |
Table 6. Alexandria Venture Investments portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Cambridge | 6 | 21% |
| San Diego | 3 | 11% |
| Seattle | 3 | 11% |
| South San Francisco | 2 | 7% |
| Watertown | 2 | 7% |
| New York | 2 | 7% |
| Durham | 2 | 7% |
| Toronto | 2 | 7% |
| Palo Alto | 1 | 4% |
| Culver City | 1 | 4% |
| La Jolla | 1 | 4% |
| San Francisco | 1 | 4% |
Table 7. Alexandria Venture Investments portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 1 | 20% | $62.5M |
| June 2026 | 2 | 40% | $140.0M |
| April 2026 | 1 | 20% | $1.6M |
| November 2025 | 1 | 20% | $115.0M |
Table 8. Alexandria Venture Investments portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 14% | $204.1M |
| 2025 | 5 | 18% | $521.0M |
| 2024 | 9 | 32% | $639.5M |
| 2023 | 4 | 14% | $320.0M |
| 2022 | 1 | 4% | $26.0M |
| 2021 | 4 | 14% | $805.0M |
Table 9. Alexandria Venture Investments portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 4 | 14% |
| 2020 to 2022 | 10 | 36% |
| 2015 to 2019 | 11 | 39% |
| 2010 to 2014 | 2 | 7% |
| Before 2010 | 1 | 4% |
Table 10. Alexandria Venture Investments portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 3 | 11% |
| 11 to 50 | 15 | 54% |
| 51 to 100 | 3 | 11% |
| 101 to 250 | 5 | 18% |
| 251 to 500 | 2 | 7% |
Table 11. Alexandria Venture Investments portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Alexandria Venture Investments is recorded as one of its investors. On 16 November 2026 that is 28 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 17 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 28 rows: 1 have no round amount, 0 no city and 0 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many Alexandria Venture Investments portfolio companies are on the list?
- 28, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 28 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.